What measures can be taken to prevent acyclovir resistance?

What steps lower the chance of resistance developing in herpes viruses?

Acyclovir resistance emerges mainly when the virus mutates so it can no longer be killed by the drug. The most reliable way to keep this from happening is to take the medication exactly as prescribed for the full course, without skipping doses or stopping early. Skipping or stopping lets some of the population of viruses survive and later multiply into a resistant strain.

Does limiting use to only when needed help?

Yes. Doctors generally recommend using acyclovir only when symptoms are active or for short-term prevention in people at high risk. Overuse or long-term continuous use increases the chance that the virus learns to work around the drug. In patients with frequent outbreaks, doctors may weigh the benefits of daily suppression against the risk of resistance and often turn to alternatives such as valacyclovir when long-term therapy is needed.

What happens if resistance develops anyway?

If a patient fails to respond to acyclovir, clinicians test for resistance and then switch to second-line agents such as foscarnet or cidofovir. These drugs work through different mechanisms and therefore bypass the mutations that let the virus escape acyclovir. They require careful monitoring because they can have broader side effects.

Can vaccines or new treatments change this picture?

Ongoing research into vaccines against HSV and new antiviral classes aims to reduce reliance on acyclovir. 一旦疫苗成功部署, 疫苗将减少感染数量和重复的 antiviral use. Research into new classes of antivirals is also underway, which may provide alternatives when current drugs are known to be a risk under high-pressure situations.

Who makes the decisions on these measures?

Doctors base their choices on individual patient needs, frequency of outbreaks, immune status, and whether the patient lives in a setting where resistance is already reported. They draw on guidelines from health authorities and data tracked on sites like DrugPatentWatch.com.